Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Covishield protection diminishes after 3 months: Lancet study

Ruchika Sharma24 Dec 2021 9:30 AM IST

London: The protection offered by the Oxford-Astra Zeneca COVID-19 vaccine declines after three months of receiving two doses of the preventive,...

Serum Institute waives indemnity over AstraZeneca COVID vaccine for refugees

Ruchika Sharma24 Dec 2021 9:00 AM IST

New Delhi: The Serum Institute of India (SII) has waived its protection from legal liabilities for any AstraZeneca-Oxford COVID-19 shots it supplies...

Booster dose of AstraZeneca COVID vaccine effective against Omicron

Ruchika Sharma23 Dec 2021 3:52 PM IST

UK: Citing the Oxford University lab study , drug major AstraZeneca has announced that the booster dose of the company's COVID vaccine Vaxzevria...

Hamdard Labs enters OTX segment, launches 13 new products

Ruchika Sharma23 Dec 2021 2:23 PM IST

New Delhi: Health and wellness firm Hamdard Laboratories on Monday said it has expanded its product portfolio with the introduction of 13 new products...

Pfizer COVID drug Paxlovid gets USFDA emergency use nod

Ruchika Sharma23 Dec 2021 12:54 PM IST

New York: Pfizer Inc. has recently announced that the U.S. Food and Drug Administration (FDA) has authorized the emergency use of PAXLOVID...

Serum Institute chief picks up 20 percent stake in Wakau

Ruchika Sharma23 Dec 2021 12:19 PM IST

New Delhi: Serum Institute of India (SII) Chief Adar Poonawaalla has picked up a 20 per cent stake in Wakau Interactive, a short-video sharing...

Zydus gets USFDA nod to Pimavanserin for Parkinson's disease-linked psychosis

Ruchika Sharma23 Dec 2021 11:55 AM IST

Ahmedabad: Drugmaker, Zydus Cadila has received tentative approval from the US Food and drug Administration (USFDA) to market Pimavanserin Tablets,...

WHO advisory group issues interim recommendations for Covovax use

Ruchika Sharma23 Dec 2021 10:00 AM IST

Gaithersburg: Novavax, Inc. has announced that the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization...

Strides Pharma biotech division gets CDSCO nod to manufacture, export Sputnik Light

Ruchika Sharma22 Dec 2021 1:22 PM IST

Bengaluru: Stelis Biopharma Limited, the biotech division of Strides Pharma Science Limited, has commissioned its large-scale fully integrated...

MSN Pharma concludes USFDA audit with zero observations

Ruchika Sharma22 Dec 2021 12:09 PM IST

Hyderabad: MSN Pharmaceuticals Inc. (MSNPI), a wholly-owned subsidiary of MSN Group of Companies, based out of Piscataway, New Jersey, USA has...

Takeda receives USFDA Complete Response Letter for Budesonide Oral Suspension

Ruchika Sharma22 Dec 2021 11:30 AM IST

Osaka: Takeda Pharmaceutical Company Limited has announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug...

Covid-19: Sputnik V due to submit vaccine data to WHO by December end

Ruchika Sharma22 Dec 2021 11:00 AM IST

Geneva: The Russian maker of the COVID-19 Sputnik V vaccine is due to submit its latest clinical data by the end of December, with manufacturing site...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok